BRIEF—Non-profit patent licensing launched for CRISPR editing in prokaryotes

Denmark-based SNIPR Biome has announced that its patent portfolio covering the use of CRISPR/Cas systems to edit prokaryotes is now available for academic and non-profit research use without a written license.

SNIPR has developed a technology platform that uses CRISPR/Cas to precisely target and edit prokaryotes, such as bacteria. The firm’s portfolio contains more than 20 granted patents in the USA and Europe.

The portfolio broadly covers fundamental scopes protecting the use of CRISPR to combat infectious disease pathogens, modulate therapy outcomes—such as for oncology and immunology—and add new gene functions to human and animal microbiomes.